Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/085—Staphylococcus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56911—Bacteria
  • G01N33/56938—Staphylococcus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
  • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
  • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2469/00—Immunoassays for the detection of microorganisms
  • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

• Figure 2 depicts fluorescent stained blot (2A) and immunoblot (2B) of a cell 10 surface fraction from S. epidermidis 0-47 grown in 70% rabbit serum separated on pH 4-7 IPG strips in the first dimension and SDS-PAGE in the second dimension.
• the proteins in the spots were identified by mass spec analysis.
• invading bacteria Upon exposure to the bloodstream of the host, invading bacteria encounter environmental cues specific to the new environment. These cues are detected by the bacteria and signal adaptive changes in protein expression that may be detectable in cell wall purified proteins. Often, proteins and carbohydrates at the bacterial cell wall are candidates for inclusion in immunogenic compositions for treating or preventing bacterial infections. Whether an upregulated protein interacts with the host or plays a role in nutrient acquisition, it is important to the bacteria and therefore plays a role in survival of the bacteria and pathogenesis. Growth of bacteria in body fluids (ie. serum, peritoneal dialysate fluid, and urine) has been used as a model system to mimic some of the signals bacteria encounter within the host. See Wiltshire, M.D. and S.J.
• body fluids ie. serum, peritoneal dialysate fluid, and urine
• oligonucleotide primers may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof.
• the sequence of such primers is designed using a polynucleotide described herein for use in detecting, amplifying or mutating a defined segment of an ORF polynucleotide that encodes a Staphylococcus epidermidis polypeptide from prokaryotic cells using polymerase chain reaction (PCR) technology.
• PCR polymerase chain reaction
• Biological equivalents or variants of Staphylococcus epidermidis include both functional and non-functional Staphylococcus epidermidis polypeptides.
• Functional biological equivalents or variants are naturally occurring amino acid sequence variants of a Staphylococcus epidermidis polypeptide that maintains the ability to elicit an immunological or antigenic response in a subject.
• Functional variants will typically contain only conservative substitutions of one or more amino acids of one of SEQ ID NO: 1 through SEQ ID NO: 32, or substitution, deletion or insertion of non- critical residues in non-critical regions of the polypeptide (e.g., not in regions containing antigenic determinants or protective epitopes).
• the recombinant host cells are prokaryotic host cells.
• the recombinant host cells of the invention are bacterial cells of the DH5 ⁇ strain of Escherichia coli.
• prokaryotes are preferred for the initial cloning of DNA sequences and constructing the vectors useful in the invention.
• E. coli K12 strains can be particularly useful.
• Other microbial strains that can be used include E. coli B, and E. co// x 1976 (ATCC No. 31537). These examples are, of course, intended to be illustrative rather than limiting.
• the 5' end of the translation initiation region of the proper translational reading frame of the polypeptide must be positioned between about 1 and about 50 nucleotides 3' of or downstream with respect to the promoter chosen.
• a polynucleotide which encodes the Staphylococcus epidermidis polypeptide.
• Colony forming units (cfu) of surviving bacteria that escape from opsonophagocytosis are determined by plating the assay mixture. Titers are reported as the reciprocal of the highest dilution that gives > 50% bacterial killing, as determined by comparison to assay controls. Specimens that demonstrate less than 50% killing at the lowest serum dilution tested (1 :8), are reported as having an OPA titer of 4. The highest dilution tested is 1 :2560. Samples with ⁇ 50% killing at the highest dilution are repeated, beginning with a higher initial dilution. The method described above is a modification of Gray's method (Gray, Conjugate Vaccines Supplement, p. 694-697, 1990).
• the active compounds are prepared with carriers that will 5 protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
• Example 1 Bacterial Growth in 70% Serum The following examples were performed using the clinical isolate

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Mycology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Physics & Mathematics (AREA)
• General Physics & Mathematics (AREA)
• Cell Biology (AREA)
• Virology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=37595601

Family Applications (1)

Country Status (13)

Cited By (3)

Families Citing this family (8)

Family Cites Families (46)

• 2005
  • 2005-10-19 EP EP10182797A patent/EP2298341A3/en not_active Withdrawn
  • 2005-10-19 EP EP09008910A patent/EP2213298A3/en not_active Withdrawn
  • 2005-10-19 EP EP10182802A patent/EP2340848A3/en not_active Withdrawn
  • 2005-10-19 KR KR1020077011032A patent/KR20070068455A/ko not_active Withdrawn
  • 2005-10-19 US US11/665,940 patent/US8445000B2/en not_active Expired - Fee Related
  • 2005-10-19 CA CA002583121A patent/CA2583121A1/en not_active Abandoned
  • 2005-10-19 EP EP05858253A patent/EP1802335A2/en not_active Withdrawn
  • 2005-10-19 WO PCT/US2005/037746 patent/WO2007001423A2/en not_active Ceased
  • 2005-10-19 AU AU2005333603A patent/AU2005333603A1/en not_active Abandoned
  • 2005-10-19 CN CNA2005800360186A patent/CN101175508A/zh active Pending
  • 2005-10-19 BR BRPI0516974-7A patent/BRPI0516974A/pt not_active IP Right Cessation
  • 2005-10-19 TW TW094136450A patent/TW200619228A/zh unknown
  • 2005-10-19 JP JP2007538033A patent/JP2008517918A/ja active Pending
  • 2005-10-20 AR ARP050104384A patent/AR051826A1/es unknown
• 2007
  • 2007-04-12 IL IL182546A patent/IL182546A0/en unknown
  • 2007-04-20 ZA ZA200703274A patent/ZA200703274B/xx unknown
• 2013
  • 2013-02-06 JP JP2013021337A patent/JP2013121981A/ja active Pending
  • 2013-04-19 US US13/866,288 patent/US20130209501A1/en not_active Abandoned
• 2015
  • 2015-03-31 US US14/674,512 patent/US20150196629A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events